Target intelligence / Profile preview

Osteocrin (OSTN)

Target
OSTN
Molecular classification
Other (Secreted protein, Myokine), Ligand (signaling receptor binding protein)
01

Overview

Osteocrin (OSTN) is a secreted peptide, classified as a myokine, with key roles in bone, muscle, and neuronal physiology. In skeletal tissue, it modulates bone mineralization and osteocyte dendrite formation by interacting with the natriuretic peptide system (notably via NPR-C), tightly regulated by vitamin D and development. In muscle, as musclin, OSTN responds to nutritional and hormonal signals and is linked to muscle adaptation, protection against cardiac dysfunction, fibrosis, and diabetic complications[1][2]. In the primate nervous system, OSTN is an activity-induced gene in excitatory cortical neurons, where it restricts dendritic overgrowth, influencing unique features of neuronal structure and function; higher OSTN expression is linked with reduced tau pathology in Alzheimer's disease[3]. OSTN also regulates proteasome function in cardiomyocytes via PKG-dependent pathways, underpinning its cardioprotective effects, especially in diabetes-related cardiac disorders[2]. Its expression is increased by physical activity, enriched at the myotendinous junction, and varies with health and disease states.

Other names
MusclinProcessed osteocrinMUSCLINosteocrin
02

Mechanism of action

Augmentation of natriuretic peptide signaling via NPR-C binding. Restoration of PKG-dependent proteasomal activity in heart muscle. Autophagy pathway modulation (liver protection via SIRT7). Regulation of dendritic complexity in neurons (activity-dependent restriction).

03

Biological functions

Regulation of neuronal dendritic growthModulation of bone mineralizationMyokine-mediated signalingCardiac protection and remodelingRegulation of proteasomal activity in cardiomyocytesRegulation of muscle adaptation to exercise
04

Disease associations

Cardiovascular disease (e.g., diabetic cardiomyopathy, cardiac dysfunction, heart failure)Neurodegenerative disease (implicated in Alzheimer’s pathology, dendritic connectivity)Diabetic complications (nephropathy)Musculoskeletal adaptation/repair
05

Safety considerations

No major safety concerns or therapeutic liabilities reported; therapeutic applications are under preclinical study[2]
06

Interacting drugs

Sildenafil (synergistic cardioprotection observed in animal models[2])
07

Biomarkers

Increased OSTN mRNA and protein expression (e.g., in response to exercise, cardiac injury, or neuronal activity[3])Reduced OSTN levels linked to disease states (e.g., heart failure, diabetic cardiomyopathy[2])

Beyond the preview

Go deeper on Osteocrin (OSTN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Osteocrin (OSTN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call